percutaneous coronary intervention

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathMACE

anti inflammatory drugs

pexelizumab
APEX-AMI, 2007          NCTpexelizumabplaceboLow risk of bias negative4%

anti-anginal drugs

nicorandil
Nishimura, 2009   nicorandilcontrolRisk of bias -

anticoagulant

not classified
Brieger     enoxaparinUFH -
bivalirudin
REPLACE-2, 2003         bivalirudinheparin + GP2b3a inhibitorsLow risk of bias -
HORIZONS-AMI (Stone), 2008        NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias suggesting-34%-1%
ACUITY (Stone) (bivalirudin alone), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias -
Kleiman, 2002     bivalirudin + eptifibatideheparin + GP2b3a inhibitorsExploratory -
ISAR-REACT 3, 2008    NCTbivalirudinUFHLow risk of bias -
REPLACE-1, 2004     bivalirudinUFHExploratory negative-100%
BAT (Bittl), 1995             bivalirudinUFHLow risk of bias suggesting123%-7%
ARMYDA BIVALVE   bivalirudinUFH -
NAPLES (Tavano), 2009     bivalirudinUFH plus tirofibanRisk of bias suggesting
dalteparin
Natarajan (without antiGp2b3a), 2003   dalteparinUFH -
Natarajan (+ antiGp2b3a), 2003   dalteparinUFH + anti Gp2b3a -
enoxaparin
STEEPLE, 2006      NCTenoxaparinUFHRisk of bias -
Rabah, 1999     enoxaparinUFHExploratory negative
CRUISE, 2003     enoxaparinUFHExploratory negative13%
Galeote, 2001   enoxaparinUFHnegative63%
Dudek, 2000   enoxaparinUFHnegative25%
Dudek b (enox alone), 2000   enoxaparinUFH -
Drozd, 2001   enoxaparinUFHnegative
ATOLL, 2010   enoxaparinUFHRisk of bias -
Dubek b (+abciximal), 2001   enoxaparin+abciximabUFH -
reviparin
REDUCE, 1996     reviparinUFHLow risk of bias suggesting-52%

antiplatelets drug

not classified
DECLARE-LONG II , 2011      -
OPTIMIZE, 2013      NCT3 months DAPT 12 months DAPTRisk of bias -
EXCELLENT, 2011      NCT6-month dual antiplatelet therapy12 months dual antiplateletnegative76%
PRODIGY, 2011      NCT24 months of dual antiplatelet treatment6 months dual antiplateletnegative 7%
WOEST    NCTtriple therapydual antiplatelet therapy -
RESET    NCTEndeavor stent and three months of DAPTstandard 12-month DAPT and other DESnegative60%
DES-LATE, 2010    NCTprolonged dual antiplatelet therapy12 months dual antiplateletRisk of bias negative52%65%
ISAR-SAFE, 2009      NCT12 months dual antiplatelet6 months dual antiplateletLow risk of bias -
CILON-T, 2010     triple antiplateletdual antiplatelet therapyExploratory negative-33%-7%
cilostazol
Kunishima, 1997     cilostazolaspirinnegative-100%
Sekiya, 1998     cilostazol + aspirinaspirinnegative-100%
Kozuma, 2001     cilostazol + aspirinticlopidine + aspirinnegative-100%
Ochiai, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Park, 1999     cilostazol + aspirinticlopidine + aspirinnegative97%
Yoon, 1999     cilostazol + aspirinticlopidine + aspirinnegative-32%
Kamishirado, 2002     cilostazol + aspirinticlopidine + aspirinnegative-100%
clopidogrel
REAL-LATE, ZEST-LATE, 2010      NCTclopidogrel+aspirinaspirinnegative52%
GRAVITAS, 2011      NCThigh-dose clopidogrelnormal-dose clopidogrelRisk of bias negative-30%
Müller, 2000     clopidogrel + aspirinticlopidine + aspirinnegative78%
CLASSICS, 2000     clopidogrel + aspirinticlopidine + aspirinnegative31%
TOPPS, 2001     clopidogrel + aspirinticlopidine + aspirinnegative-16%
Piamsomboon, 2001   clopidogrel + aspirinticlopidine + aspirinnegative-100%
ticlopidine
STARS (vs aspirin), 1998     ticlopidine + aspirinaspirinsuggesting-85%
Hall, 1996     ticlopidine + aspirinaspirinnegative98%
FANTASTIC, 1998     ticlopidine + aspirincoumadin + aspirinnegative-30%
ISAR, 1996     ticlopidine + aspirincoumadin + aspirinsuggesting-75%
Foussas, 2000   ticlopidine + aspirincoumadin + aspirinsuggesting-69%
MATTIS, 1998     ticlopidine + aspirincoumadin + aspirinnegative-49%
STARS (vs coumadin+asp), 1998     ticlopidine + aspirincoumadin + aspirinsuggesting-80%

antithrombotics

not classified
EPIC (without infusion), 1991   -
IMPACT (12h), 1993   -
IMPACT-II (0.75µg), 1994   -
EXCELLENT, 2011      NCT6-month dual antiplatelet therapy12 months dual antiplateletnegative76%
Finci, 1989   placebonegative
Oriol, 1995   placebonegative
TRA-PCI, 2009      NCTSCH 530348placeboLow risk of bias -
Brieger     enoxaparinUFH -
DES-LATE, 2010    NCTprolonged dual antiplatelet therapy12 months dual antiplateletRisk of bias negative52%65%
ISAR-SAFE, 2009      NCT12 months dual antiplatelet6 months dual antiplateletLow risk of bias -
CILON-T, 2010     triple antiplateletdual antiplatelet therapyExploratory negative-33%-7%
abciximab
RAPPORT, 1998     Abciximabplacebo -
ADMIRAL, 2001     Abciximabplacebo -
CADILLAC, 2002     Abciximabplacebo -
EPIC (with infusion), 1994     Abciximabplacebo -
EPILOG, 1997     Abciximabplacebo -
EPISTENT, 1998         Abciximabplacebo -
CAPTURE, 1997     Abciximabplacebo -
ERASER, 1999     Abciximabplacebo -
Petronio, 2002     Abciximabplacebo -
Simoons, 1994   Abciximabplacebo -
Kini, 2001     Abciximabplacebo -
Tamburino, 2002   Abciximabplacebo -
ISAR-2, 2000     Abciximabplacebo -
aspirin
Taylor (Perth), 1991     aspirinplaceboLow risk of bias negative
M-HEART II (aspirin), 1995     aspirinplaceboLow risk of bias negative
bivalirudin
REPLACE-2, 2003         bivalirudinheparin + GP2b3a inhibitorsLow risk of bias -
HORIZONS-AMI (Stone), 2008        NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias suggesting-34%-1%
ACUITY (Stone) (bivalirudin alone), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias -
Kleiman, 2002     bivalirudin + eptifibatideheparin + GP2b3a inhibitorsExploratory -
ISAR-REACT 3, 2008    NCTbivalirudinUFHLow risk of bias -
REPLACE-1, 2004     bivalirudinUFHExploratory negative-100%
BAT (Bittl), 1995             bivalirudinUFHLow risk of bias suggesting123%-7%
ARMYDA BIVALVE   bivalirudinUFH -
NAPLES (Tavano), 2009     bivalirudinUFH plus tirofibanRisk of bias suggesting
cangrelor
CHAMPION PHOENIX, 2013        NCTcangrelorclopidogrelLow risk of bias suggesting0%-20%
CHAMPION-PCI, 2009      NCTcangrelor up frontclopidogrel up frontLow risk of bias negative59%-33%
CHAMPION-PLATFORM, 2009    NCTcangrelor up frontdelayed clopidogrelLow risk of bias negative
cilostazol
Kunishima, 1997     cilostazolaspirinnegative-100%
Sekiya, 1998     cilostazol + aspirinaspirinnegative-100%
Kozuma, 2001     cilostazol + aspirinticlopidine + aspirinnegative-100%
Ochiai, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Park, 1999     cilostazol + aspirinticlopidine + aspirinnegative97%
Yoon, 1999     cilostazol + aspirinticlopidine + aspirinnegative-32%
Kamishirado, 2002     cilostazol + aspirinticlopidine + aspirinnegative-100%
clopidogrel
GRAVITAS, 2011      NCThigh-dose clopidogrelnormal-dose clopidogrelRisk of bias negative-30%
Müller, 2000     clopidogrel + aspirinticlopidine + aspirinnegative78%
CLASSICS, 2000     clopidogrel + aspirinticlopidine + aspirinnegative31%
TOPPS, 2001     clopidogrel + aspirinticlopidine + aspirinnegative-16%
Piamsomboon, 2001   clopidogrel + aspirinticlopidine + aspirinnegative-100%
dalteparin
Natarajan (without antiGp2b3a), 2003   dalteparinUFH -
Natarajan (+ antiGp2b3a), 2003   dalteparinUFH + anti Gp2b3a -
dipyridamol
Schwartz (Toronto), 1988   aspirin + dipyridamolplaceboLow risk of bias suggesting
White (aspirin+dipiridamol), 1991   aspirin + dipyridamolplacebonegative
Nye (Dunedin), 1990   aspirin + dipyridamolplacebonegative
Mayo-PTCA, 1989   aspirin + dipyridamolplacebonegative
elinogrel
INNOVATE PCI          NCTelinogrelclopidogrel -
enoxaparin
STEEPLE, 2006      NCTenoxaparinUFHRisk of bias -
Rabah, 1999     enoxaparinUFHExploratory negative
CRUISE, 2003     enoxaparinUFHExploratory negative13%
Galeote, 2001   enoxaparinUFHnegative63%
Dudek, 2000   enoxaparinUFHnegative25%
Dudek b (enox alone), 2000   enoxaparinUFH -
Drozd, 2001   enoxaparinUFHnegative
ATOLL, 2010   enoxaparinUFHRisk of bias -
Dubek b (+abciximal), 2001   enoxaparin+abciximabUFH -
eptifibatide
IMPACT (4h), 1995     Eptifibatideplacebo -
IMPACT-II (0.5µg), 1997     Eptifibatideplacebo -
ESPRIT, 2000     Eptifibatideplacebo -
Harrington, 1995     Eptifibatideplacebo -
prasugrel
TRITOM TIMI 38 (PCI subgroup), 2009     prasugrelclopidogrel -
JUMBO-TIMI 26, 2005   prasugrelclopidogrelLow risk of bias negative
reviparin
REDUCE, 1996     reviparinUFHLow risk of bias suggesting-52%
sulotroban
M-HEART II (sulotroban), 1995   sulotrobanplaceboLow risk of bias -
ticlopidine
TACT, 1990   ticlopidineplacebonegative
White (ticlopidine), 1991   ticlopidineplacebo -
STARS (vs aspirin), 1998     ticlopidine + aspirinaspirinsuggesting-85%
Hall, 1996     ticlopidine + aspirinaspirinnegative98%
FANTASTIC, 1998     ticlopidine + aspirincoumadin + aspirinnegative-30%
ISAR, 1996     ticlopidine + aspirincoumadin + aspirinsuggesting-75%
Foussas, 2000   ticlopidine + aspirincoumadin + aspirinsuggesting-69%
MATTIS, 1998     ticlopidine + aspirincoumadin + aspirinnegative-49%
STARS (vs coumadin+asp), 1998     ticlopidine + aspirincoumadin + aspirinsuggesting-80%
tirofiban
RESTORE, 1997       Tirofibanplacebo -
Kereiakis, 1996     Tirofibanplacebo -

bioresorbable vascular scaffold

not classified
ABSORB III, 2015    NCT -
LEADERS FREE      NCT -
BIOFLOW-V    NCTbiodegradable polymer sirolimus-eluting stent durable polymer everolimus-eluting stent -
ABSORB II      NCT(Absorb, Abbott Vascular,everolimus-eluting metallic stent -

pre treatment for PCI

cangrelor
CHAMPION-PCI, 2009      NCTcangrelor up frontclopidogrel up frontLow risk of bias negative59%-33%

proton-pump inhibitors

not classified
COGENT, 2009    NCTomeprazoleplaceboLow risk of bias suggesting
OCLA, 2008    NCTomeprazoleplaceboLow risk of bias -
PACA, 2009   pantoprazoleomeprazole -

radial access

not classified
Grinfeld, 1996   radialfemoral -
Mann , 1996   radialfemoral -
ACCESS , 1997     radialfemoralnegative+Infini%
BRAFE , 1997     radialfemoralnegative
Cooper , 1999   radialfemoralnegative
Mann , 1998     radialfemoralnegative
Monsegu , 2000   radialfemoral -
CARAFE , 2001     radialfemoral -
Gorge and Kirstein, 2001   radialfemoralnegative
Moriyama , 2002   radialfemoral -
TEMPURA , 2003     radialfemoralnegative-47%
OCTOPLUS , 2004     radialfemoralsuggesting-36%
Tian , 2003   radialfemoral -
Reddy , 2004     radialfemoral -
RADIAL AMI , 2005     radialfemoralnegative-100%
Achenbach , 2005   radialfemoralnegative
OUTCLAS , 2005     radialfemoralnegative50%
FARMI , 2007     radialfemoralnegative
Lange and von Boetticher, 2006     radialfemoral -
RADIAMI , 2007   radialfemoralnegative-100%
Bodi, 2008   radialfemoralsuggesting-75%
Li , 2007     radialfemoral -
Vazquez-Rodriguez, 2004   radialfemoralnegative-9%

restenosis prevention

amlodipine
Jorgensen (NICOLE), 2001     amlodipineplaceboLow risk of bias suggesting
diltiazem
Corcos, 1985   diltiazemcontrolnegative
O’Keefe, 1991   diltiazemplaceboLow risk of bias negative
Unverdorben, 1996   diltiazemplaceboLow risk of bias suggesting
nifedipine
Whitworth, 1986   nifedipineplaceboLow risk of bias negative
nisoldipine
Dens (CAPARES), 2000     nisoldipineplaceboLow risk of bias suggesting
verapamil
Hoberg, 1994     verapamilplaceboLow risk of bias negative

statins

not classified
Briguori, 2004     various statinsplacebosuggesting
atorvastatin
NAPLES II (Briguori), 2009     atorvastatincontrolsuggesting
ARMYDA, 2004     atorvastatinplaceboLow risk of bias suggesting
ARMYDA-RECAPTURE, 2009   atorvastatin reloadplaceboLow risk of bias suggesting-100%-61%
GAIN, 2001